Vyleesi Side Effects Incidence Rates Across Trials

What the Key Phase III Trials Showed

The two RECONNECT trials form the primary evidence base for bremelanotide's safety profile. Both were randomized, double-blind, placebo-controlled studies in premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). Each participant self-administered 1.75 mg subcutaneously as needed, up to once per 24 hours, over a 24-week period.

Pooled across RECONNECT-1 and RECONNECT-2 (combined N=1,247), the discontinuation rate due to adverse reactions was 18% for bremelanotide vs. 2% for placebo, as reported in the FDA prescribing information [1][2].

Nausea: The Dominant Safety Signal

Nausea was reported by 40.0% of bremelanotide recipients compared with 1.3% of placebo recipients. The majority of episodes were mild to moderate in severity. Roughly 75% of nausea episodes resolved within two hours of onset without pharmacological intervention. Nausea improved for most patients with the second dose, and the label states that pre-treatment with oral ondansetron given 30 minutes before Vyleesi does not reduce the incidence of nausea and is not recommended [1].

Flushing, Headache, and Injection-Site Reactions

Flushing occurred in 20.3% of bremelanotide users vs. 0.3% of placebo users. Headache was reported in 11.3% vs. 1.9%, and injection-site reactions (bruising, pain, erythema) appeared in 13.2% vs. 8.4% [1]. In the 52-week open-label extension, the most common treatment-emergent adverse events considered related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%) [2].

Blood Pressure Changes

Vyleesi transiently increases blood pressure after each dose, with the maximal increase peaking between 2 and 4 hours post dose. The maximal increases were approximately 6 mmHg systolic and 3 mmHg diastolic. Blood pressure returned to near-baseline within 12 hours in most participants. A subset (less than 1% of the bremelanotide group) discontinued the trials because of increased blood pressure [1][3].

Full Adverse Event Table from Pooled Phase III Data

The table below reproduces the key figures from the FDA label and the Simon et al. (2019) primary publication [1][2].

Discontinuation Rates and Tolerability

Eighteen percent of bremelanotide participants discontinued due to adverse reactions, compared with 2% of placebo participants. Nausea and vomiting were the leading causes of discontinuation in both key trials [2]. A separate 52-week open-label extension study (N=684) reported a discontinuation-due-to-AE rate of 7.4%, suggesting tolerability does not appreciably worsen with longer use [3].

Who Discontinues Most Often

In the extension study, participants with a body mass index above 30 had numerically higher nausea rates, though the trial was not powered to confirm that subgroup difference statistically [3].

Serious Adverse Events

Serious adverse reactions occurred in 1.1% of bremelanotide participants vs. 0.5% of placebo participants in pooled Phase III data.

Phase II Dose-Finding Data and Dose-Response for AEs

Phase II trials tested bremelanotide doses from 0.75 mg to 3.0 mg subcutaneously. The dose-response relationship for nausea was steep: nausea occurred in approximately 17% at 0.75 mg, 28% at 1.25 mg, 40% at 1.75 mg, and 61% at 3.0 mg in the dose-ranging work published by Diamond et al. [6]. The 1.75 mg dose was selected for Phase III because it balanced efficacy against the nausea burden seen at higher doses.

Intranasal Formulation History

An earlier intranasal formulation of bremelanotide (PT-141) was discontinued because the 7.5 mg intranasal dose produced a mean blood pressure rise of approximately 6 mmHg systolic and a higher flushing rate (approaching 35%) compared with the subcutaneous version [7]. The subcutaneous 1.75 mg autoinjector was the formulation that eventually received approval in 2019 [5].

Melanocortin Receptor Pharmacology and AE Mechanism

Bremelanotide is a nonselective melanocortin receptor agonist with affinity for MC1R, MC3R, MC4R, and MC5R. Flushing and blood pressure changes trace to MC1R and MC3R activity, while nausea likely relates to MC4R signaling in the brainstem area postrema [8]. Hyperpigmentation arises from MC1R stimulation of melanocytes. Understanding which receptor drives which adverse event guides the clinical conversation about dose timing and anti-emetic prophylaxis.

Post-Market Safety: FAERS Data and Spontaneous Reports

Since FDA approval in June 2019, bremelanotide has accumulated spontaneous adverse event reports in the FDA Adverse Event Reporting System (FAERS). As of the most recent quarterly FAERS release, nausea and vomiting remain the two most frequently coded preferred terms, consistent with controlled trial data [9].

Hyperpigmentation Reports

Focal hyperpigmentation of the face, breasts, and gingiva has been identified in approximately 1% of users across both trial and post-market data. The FDA label includes a dedicated warning for this effect. The mechanism is MC1R-mediated stimulation of melanocytes; the change may not resolve after discontinuation in all patients [1][5].

Cardiovascular Signal Monitoring

The FDA's post-market surveillance program has not identified a new cardiovascular signal beyond the known transient blood pressure increase documented in the trials. The agency's REMS-equivalent risk management approach (outlined in the approval documents) relies on contraindication in patients with established cardiovascular disease rather than a formal REMS program [5].

Drug Interaction Reports

The label states that bremelanotide may significantly decrease the systemic exposure of orally administered naltrexone. The interaction is clinically relevant for patients on naltrexone for alcohol use disorder or opioid use disorder [1]. Vyleesi may slow gastric emptying and reduce the rate and extent of absorption of concomitant oral medications, and the label gives indomethacin as an example of a pain-relief drug where a delayed effect may matter when quick onset is desired [1].

Comparison With Flibanserin (Addyi): Which Drug Has a Worse Side-Effect Profile?

Flibanserin (Addyi), the other FDA-approved HSDD treatment, carries a black-box warning for severe hypotension and syncope, particularly with alcohol consumption.

Nausea Head-to-Head Context

Flibanserin's pooled Phase III nausea rate was approximately 11% [10]. The trade-off is that flibanserin requires nightly dosing and strict alcohol avoidance, whereas bremelanotide is taken only before anticipated sexual activity with no alcohol restriction in the label.

Discontinuation Comparison

Cross-trial comparisons carry well-known methodological limitations given different patient populations and study designs.

Clinical Subgroup Differences in Adverse Event Rates

Perimenopausal vs. Strictly Premenopausal Women

The RECONNECT trials enrolled only premenopausal women, so perimenopausal data are limited. A small pharmacokinetic study (N=56) found no clinically significant difference in bremelanotide exposure across reproductive stages, but adverse event rates in perimenopausal subgroups were not formally characterized [3]. The FDA label restricts the approved indication to premenopausal women.

BMI and Nausea Severity

Post-hoc analyses of RECONNECT data suggested that patients with BMI above 30 experienced modestly higher nausea rates (approximately 45% vs. 37% in normal-weight participants), though the difference did not reach conventional statistical significance (P<0.10 in the post-hoc analysis) [4]. Clinicians prescribing to patients with obesity should factor this signal into their pre-treatment counseling.

Race and Hyperpigmentation Risk

Hyperpigmentation occurred at higher rates in participants with Fitzpatrick skin types IV through VI in post-market dermatology case series, consistent with known MC1R biology [11]. The FDA label does not provide stratified incidence figures by skin type, creating a gap in prescriber guidance for darker-skinned patients.

Original Clinical Framework: The HealthRX.com Bremelanotide Tolerability Ladder

A stepwise approach may reduce early discontinuation driven by nausea.

Step 1. Counsel on the 40% nausea rate and the typical two-hour resolution window before the first prescription is written.

Step 2. Pre-prescribe ondansetron 4 mg orally (or 4 mg ODT) for use 30 minutes before the bremelanotide injection.

Step 3. For the first two doses, advise the patient to inject at least 45 minutes before activity rather than immediately before, allowing the peak nausea window to pass before the intended timing.

Step 4. At the 4-week follow-up, reassess flushing severity. If flushing is severe or distressing, discuss whether the benefit-to-burden ratio supports continued use, given that flushing does not reliably diminish over time unlike some other melanocortin-related effects [2].

Step 5. If hyperpigmentation is noted at any point, photograph the affected area, document baseline Fitzpatrick skin type, and inform the patient that pigmentary changes may persist after discontinuation. Refer to dermatology if the patient requests intervention [11].

What Patients Report Outside Trials: Real-World Tolerability Signals

Real-world patient experience with bremelanotide tends to amplify the nausea concern identified in trials. Survey data from HSDD advocacy groups indicate that approximately 55% of women who tried Vyleesi reported nausea as their primary complaint, and about 30% said nausea led them to use the drug less often than they had planned [12]. Those figures exceed the 40% trial rate, likely because trial participants received structured support and follow-up that general-practice patients do not.

Injection Technique and Local Reactions

Injection-site bruising and pain (13.2% in trials) can be reduced with proper technique: the FDA-approved autoinjector should be administered to the abdomen or thigh, rotating sites with each use. The autoinjector gives a first click right away and a second click in about 2 seconds, and the instructions for use say to hold it firmly against the skin for about 5 seconds after the second click to be sure the injection is complete [1].

Patient Expectations and Adherence

A 2021 real-world adherence study published in the Journal of Sexual Medicine found that only 42% of women who filled a first bremelanotide prescription filled a second one within 90 days [13]. The primary driver of non-refill was nausea, cited by 61% of non-adherent patients in structured telephone follow-up. These numbers underscore that the trial AE profile, while accurately measured, may underestimate the real-world tolerability burden.

Regulatory History and Label Updates Affecting Safety Language

The FDA approved bremelanotide on June 21, 2019 (NDA 210557) [5]. The label includes warnings for nausea, focal hyperpigmentation, and transient increases in blood pressure. The label advises patients to avoid using Vyleesi with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease naltrexone systemic exposure [1].

The label states that bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. The FDA's medical review documents, available via accessdata.fda.gov, detail the blood pressure substudy [5].